Research Output per year
Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.
- 3 Similar Profiles
Heterografts
Medicine & Life Sciences
irinotecan
Medicine & Life Sciences
Neoplasms
Medicine & Life Sciences
Pediatrics
Medicine & Life Sciences
Rhabdomyosarcoma
Medicine & Life Sciences
Sirolimus
Medicine & Life Sciences
Topotecan
Medicine & Life Sciences
Cell Line
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Research Output 1975 2018
Abemaciclib is active in preclinical models of Ewing sarcoma via multipronged regulation of cell cycle, DNA methylation, and interferon pathway signaling
Dowless, M., Lowery, C. D., Shackleford, T., Renschler, M., Stephens, J., Flack, R., Blosser, W., Gupta, S., Stewart, J., Webster, Y., Dempsey, J., VanWye, A. B., Ebert, P., Iversen, P., Olsen, J. B., Gong, X., Buchanan, S., Houghton, P. J. & Stancato, L., Dec 1 2018, In : Clinical Cancer Research. 24, 23, p. 6028-6039 12 p.Research output: Contribution to journal › Article
Ewing's Sarcoma
DNA Methylation
Interferons
Cell Cycle
irinotecan
Classical NF-κB metabolically reprograms sarcoma cells through regulation of hexokinase 2
Londhe, P., Yu, P. Y., Ijiri, Y., Ladner, K. J., Fenger, J. M., London, C., Houghton, P. J. & Guttridge, D. C., Apr 11 2018, In : Frontiers in Oncology. 8, APR, 104.Research output: Contribution to journal › Article
Hexokinase
Sarcoma
Metabolome
Glycolysis
Osteosarcoma
ETV7 is an essential component of a rapamycin-insensitive mTOR complex in cancer
Harwood, F. C., Klein Geltink, R. I., O’Hara, B. P., Cardone, M., Janke, L., Finkelstein, D., Entin, I., Paul, L., Houghton, P. J. & Grosveld, G. C., Sep 12 2018, In : Science Advances. 4, 9, eaar3938.Research output: Contribution to journal › Article
Sirolimus
Neoplasms
Rhabdomyosarcoma
Penetrance
Protein-Serine-Threonine Kinases
Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program
Kurmasheva, R. T., Kurmashev, D., Reynolds, C. P., Kang, M., Wu, J., Houghton, P. J. & Smith, M. A., Feb 1 2018, In : Pediatric Blood and Cancer. 65, 2, e26825.Research output: Contribution to journal › Article
Melphalan
Cisplatin
Pediatrics
Heterografts
Disease-Free Survival
KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism
Vaseva, A. V., Blake, D. R., Gilbert, T. S. K., Ng, S., Hostetter, G., Azam, S. H., Ozkan-Dagliyan, I., Gautam, P., Bryant, K. L., Pearce, K. H., Herring, L. E., Han, H., Graves, L. M., Witkiewicz, A. K., Knudsen, E. S., Pecot, C. V., Rashid, N., Houghton, P. J., Wennerberg, K., Cox, A. D. & 1 others, Nov 12 2018, In : Cancer Cell. 34, 5, p. 807-822.e7Research output: Contribution to journal › Article
Adenocarcinoma
Ubiquitin-Protein Ligases
Protein Stability
Proteasome Endopeptidase Complex
Growth
Press/Media
Discovery of a cancer promoter offers pathway to overcome drug resistance
9/12/18
1 item of media coverage
Press/Media: Press / Media
Discovery of Cancer Promoter Offers Pathway to Overcome Drug Resistance
9/12/18
1 item of media coverage
Press/Media: Press / Media
St. Jude Children's Research Hospital: Discovery of a cancer promoter offers pathway to overcome drug resistance
9/12/18
1 item of media coverage
Press/Media: Press / Media
Another view ; For children with cancer, the STAR Act is a victory
Gail Tomlinson, Gregory Aune & Peter J Houghton
6/11/18
1 item of media coverage
Press/Media: Press / Media
PROFILE: Collaborations to cure childhood cancer
6/7/18
1 item of media coverage
Press/Media: Press / Media